Endometrial Cancer – Adding Herceptin to the Standard Protocol Prolongs Patients’ Lives

Background – Endometrial cancer and this trial

Uterine-serous-carcinoma, USC, is an aggressive variant of endometrial cancer.

This phase II trial evaluated Carboplatin+Taxol versus Herceptin +Carboplatin+Taxol in patients with advanced or recurrent uterine serous carcinomas that express HER2, HER2+. Eligible patients had stage III to IV metastatic or recurrent disease.

The addition of Herceptin improved both the time until worsening of the disease and survival, with the greatest benefit observed for patients with advanced or metastatic disease.


  • 61 patients were enrolled to the study
  • Median time until worsening of disease was 8.0 months in the Carboplatin+Taxol group versus 12.9 months in the Herceptin+Carboplatin+Taxol group
  • Median time until worsening of disease was 9.3 months versus 17.7 months in the Herceptin group among 41 patients with stage III to IV disease for whom this was their primary treatment
  • Median time until worsening of disease was 7.0 months versus 9.2 months in the Herceptin group among 17 patients with recurrent disease
  • Median survival was higher in the Herceptin group – 29.6 months versus 24.4 months.
  • Side effects were not different between groups

Conclusions in Endometrial cancer

Addition of Herceptin to Carboplatin+Taxol increased the time until the disease worsened and longevity in women with advanced/recurrent HER2+ USC, with the greatest benefit seen for the treatment of stage III to IV metastatic disease.

The best treatment for a cancer patient is to get the most advanced cancer drugs in advanced stages of development. There, the hope and the chance to extend life go far beyond the standard protocols.

Contact us to find out what is the best treatment for YOU


Because we, do not give up on life!

Contact us 24/7 –

Call center +44.2082.426.039

For further reading>>

About Clinical Trials>>

A clinical trial is a study where human beings receive the treatment, and there are approx.

Under the definition of “NEW THERAPY”, are: a new drug, a new indication for a known drug, or a new technique of performing a surgery, or providing radiation therapy. A new therapy may be a treatment using a new technique (such as gene manipulation) or a new medical device.

20,000 cancer clinical trials are available to cancer patients worldwide. Less than a few percent of these studies are open in each country.

Uterine Cancer - Adding Herceptin to Advanced and Metastatic Disease
Uterine Cancer – Adding Herceptin to Advanced and Metastatic Disease

To check if our service suits your case
We need to talk

Improve therapeutic outcomes, prolong life and quality of life, is our main business.
We support access to and expand cancer treatments beyond the standard of care, with the most advanced and innovative treatment options in the world, personally matching the individual cancer patient’s medical condition and with the support of top tier oncologists.

Article categories

קטגוריות המאמרים

Popular topics